XZP-3287
XZP-3287 is an experimental small-molecule drug from Sihuan Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Overview
XZP-3287 is a small-molecule drug developed by Sihuan Pharmaceutical and Xuanzhu Biopharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05077449 (A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT04539496, plans to enrol 402 participants (actual) with primary completion expected 2023-07-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"XZP-3287" OR ABSTRACT:"XZP-3287") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about XZP-3287, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentSerabelisib
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentSapanisertib
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentENV-501
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentSYS6023
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentTQB2930
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentSIM0270
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentEP0062
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.
- TreatmentGLSI-100
Shares HR-positive / HER2-negative breast cancer and the tags pipeline, ctgov-ingest.